Holen Sie sich die Stockscreener-App
1.69
4.32%
0.07
Handel nachbörslich:
1.71
0.02
+1.18%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.68
24-Stunden-Volumen:
8.15M
Relative Volume:
1.95
Marktkapitalisierung:
$527.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-6.2593
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
+12.67%
1M Leistung:
+14.19%
6M Leistung:
+62.50%
1J Leistung:
+136.36%
1-Tages-Spanne:
$1.6312
$1.84
1-Wochen-Bereich:
$1.544
$1.96
52-Wochen-Spanne:
$0.515
$1.96
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.69 | 505.96M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Short Squeeze: Will Ocugen Inc benefit from sector rotation2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Forecast Cut: Will Ocugen Inc benefit from sector rotationPortfolio Performance Summary & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Ocugen Shares Stabilize Following Critical Clinical Data Release - AD HOC NEWS
Ocugen Shares Face Scrutiny Over Clinical Data Anomaly - AD HOC NEWS
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy By Investing.com - Investing.com Nigeria
Ocugen Shares Retreat as Clinical Data Fails to Meet Elevated Expectations - AD HOC NEWS
Ocugen’s ArMaDa Trial Sails With Positive Data For OCU410 - Citeline News & Insights
Ocugen (OCGN) Reports 46% Lesion Reduction in OCU410 Mid-Stage Trial - Intellectia AI
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
OS Therapies Bone Cancer Trial Data Strengthens FDA Case - Benzinga
Ocugen Faces Mounting Challenges in Vaccine Market - StocksToTrade
Ocugen Faces Sharp Stock Drop Amid Business Challenges - timothysykes.com
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Reports Encouraging 12-Month Data for OCU410 - TipRanks
Ocugen (OCGN) Reports Promising Mid-Stage Trial Results for OCU410 - GuruFocus
Ocugen posts mid-stage trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy - Investing.com
Ocugen rises as gene therapy shows promise for blinding eye disease - TradingView — Track All Markets
Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration - marketscreener.com
Eye gene therapy for geographic atrophy slows lesions 46% in study - Stock Titan
Ocugen Inc. Stock Rises Wednesday, Outperforms Market - 富途牛牛
Ocugen Shares Surge Ahead of Key Clinical Data Announcement - AD HOC NEWS
Ocugen (NASDAQ:OCGN) Hits New 1-Year HighHere's Why - MarketBeat
Ocugen Shares Surge Ahead of Pivotal Clinical Data Release - AD HOC NEWS
Ocugen to host webcast on OCU410 Phase 2 clinical trial results - Investing.com Nigeria
Ocugen (NASDAQ:OCGN) Trading Down 5.9%Should You Sell? - MarketBeat
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates - Yahoo Finance
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease - Ophthalmology Times
Ocugen Shares Surge on Clinical Validation and Upcoming Catalyst - AD HOC NEWS
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Ocugen, Inc.
Ocugen to Host Conference Call Discussing One-Year Data from OCU410 Phase 2 ArMaDa Clinical Trial - Quiver Quantitative
Ocugen Shares Surge on Promising Gene Therapy Trial Results - AD HOC NEWS
Ocugen reports positive Phase 1 trial results for Stargardt disease therapy - Investing.com Nigeria
Ocugen Shares Surge on Promising Gene Therapy Trial Data - AD HOC NEWS
OCGN stock rises pre-market after gene therapy data shows promise in rare eye disorder - MSN
Ocugen (NASDAQ:OCGN) Shares Up 9%Time to Buy? - MarketBeat
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy - Ocugen, Inc.
Ocugen announces publication of Phase 1 GARDian1 trial results for OCU410ST - TipRanks
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder - Stocktwits
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Ocugen (OCGN) Reveals Positive Trial Results for Gene Therapy OC - GuruFocus
Ocugen, Inc. Reports Positive Phase 1 Trial Results for OCU410ST in Stargardt Disease, Highlighting Safety and Efficacy - Quiver Quantitative
Gene therapy trial slows eye damage in Stargardt patients with no options - Stock Titan
Ocugen Faces Pivotal Investor Test at Key Healthcare Conference - AD HOC NEWS
Is Social Media Hype Reshaping Ocugen’s (OCGN) Gene Therapy Story More Than Its Pipeline Progress? - Sahm
Ocugen (OCGN) Valuation Check As Social Media Speculation Lifts Interest In Gene Therapy Prospects - Yahoo Finance
Ocugen Eyes a Breakout Year as It Takes Center Stage at JPM Healthcare - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Is Social Media Now Defining Ocugen's (OCGN) Gene Therapy Investment Story More Than Its Science? - Yahoo Finance
How Ocugen Inc. stock performs in stagflation2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):